Vera Therapeutics (VERA) had the highest return in January 2024 by a mid-cap US stock, returning 139.6%.

ASSET	MONTH	% RETURN
Vera Therapeutics (VERA)	January 2024	139.61%
Trump Media & Technology (DJT)	January 2024	115.14%
NewAmsterdam Pharma Company NV Ordinary Shares (NAMS)	January 2024	82.77%
WM Technology (MAPSW)	January 2024	70%
Dyne Therapeutics (DYN)	January 2024	64.36%
Edgewise Therapeutics (EWTX)	January 2024	63.13%
Rumble (RUM)	January 2024	52.22%
ZIM Integrated Shipping Services (ZIM)	January 2024	44.23%
GeneDx (WGS)	January 2024	42.59%
Oscar Health (OSCR)	January 2024	38.65%
Alvotech (ALVO)	January 2024	37.08%
Tarsus Pharmaceuticals (TARS)	January 2024	36.2%
Powell Industries (POWL)	January 2024	36.15%
Avidity Biosciences (RNA)	January 2024	35.59%
Advantage Solutions (ADVWW)	January 2024	32.01%
Merus (MRUS)	January 2024	31.61%
Viking Therapeutics (VKTX)	January 2024	30.28%
Kymera Therapeutics (KYMR)	January 2024	28.65%
CG Oncology, Inc Common stock (CGON)	January 2024	28.48%
Appfolio (APPF)	January 2024	27.49%
Grupo Financiero Galicia SA ADR (GGAL)	January 2024	26.01%
Rigetti Computing (RGTI)	January 2024	24%
Kemper (KMPR)	January 2024	23.69%
Ideaya Biosciences (IDYA)	January 2024	23.56%
Vericel Corp Ord (VCEL)	January 2024	22.38%

Mid-cap stocks are treated as having a market cap between $2B and $10B.